GSK
GSK Plc ADR
$53.66+4.60%
Setup
No setup
Buy Zone
$53.88-$56.57
Sector
Drug Manufacturers - General
Industry
Drug Manufacturers - General
52
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
GSK chart
Loading chart…
Overall Quality52
RS Rating
70
relative strength
Fundamentals
64
Solid fund-Q
Volume Demand
82
-2% vs avg
Technical Setup
75
6/8 checks
Industry/Theme
91
Drug Manufacturers - General
Trade Plan
Avoid
Entry
$53.88
Entry Zone
$53.88-$56.57
Stop / Risk
$49.57
RS Rating
70
Volume confirmed
Yes
Targets
$64.66 / $67.35
Breakout · IBD Setup
4 ✓ 4 ✗
Entry $53.88–$56.57Stop $49.57Target $64.66 / $67.35
Market regimeRange
Quality52
RS Rating70
Above 50-MA+3.98%
Above 200-MA+6.04%
VolumeConfirmed
In Buy ZoneNo
Not extendedOK
Invalidation · Close below stop
How this came together
52
MarketRange
SetupNo setup
ConfidenceExperimental · not backtested
Fund-Q64 · Solid
StatusAvoid
Stock Data
52-Week Range35 – 62
Price % Chg YTD9.42%
Price % Chg 4wk9.51%
50-Day Avg Vol3.9 Mil
P/E Ratio13.7
Market Cap$105B
SectorHealthcare
IndustryDrug Manufacturers - General
Company Fundamentals
EPS % Chg (Qtr)16.2%
Sales % Chg (Qtr)8.6%
EPS Growth 5y0.08%
Sales Growth 5y-0.31%
Annual ROE37.44%
Gross Margin72.81%
Operating Margin24.55%
Net Margin17.82%
Debt / Equity1.07
Setup levels
Current price
$53.66
Pivot
$53.88
Distance to buy
-13%
52-week range
35.45-61.69
Trigger evidence
No active trigger evidence available.
Financial health checks
4/5
Return on equity above 15%
ROE 37.44%
Net margin above 10%
Net margin 17.82%
EPS growing quarter on quarter
EPS q/q 16.2%
Sales growing quarter on quarter
Sales q/q 8.6%
Debt to equity below 1.0
D/E 1.07
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE37.44%
vs sector +14.4%
Net margin17.82%
vs sector -1.5%
Gross margin72.81%
vs sector +1.2%
EPS growth q/q16.2%
vs sector -3.0%
Sales growth q/q8.6%
vs sector -12.6%
Debt / equity1.07
vs sector +0.35
Business quality
64
GradeSolid
EPS rating44
P/E13.7
Market cap$105B
IndustryDrug Manufacturers - General
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Pass
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-07-01
Trigger date
—
Days on list
3
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.